J.P. Morgan Securities closes Kangji Medical derivative positions

J.P. Morgan Securities PLC, an associate connected with the Offeror and ultimately owned by JPMorgan Chase & Co., has disclosed multiple dealings in Kangji Medical Holdings Limited shares. These transactions, made for its own account on November 12, 2025, involved closing out various derivative contracts tied to "Other types of products."

The disclosed dealings include the closing of derivative contracts referencing securities ranging from 38,500 to 100,000 units, with closing out dates in December 2026 and November 2026. All these transactions were executed at a reference price of $9.1773. The total amounts received from these closings ranged from $353,324.93 to $917,727.10.

Following these disclosures, J.P. Morgan Securities PLC's resultant balance in Kangji Medical Holdings Limited decreased from 8,680,343 to 8,541,843 shares. Further closing out of contracts in larger tranches, up to 585,000 units, continued to reduce the balance, with the final reported balance after these dealings standing at 6,677,843 shares.